(Q33652033)

28 July 2017

1 reference

title

Role of fibrates in the management of hypertriglyceridemia (English)

1 reference

28 July 2017

1 reference

Rader DJ

1

1 reference

28 July 2017

Haffner SM

series ordinal

2

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

American Journal of Cardiology

28 July 2017

1 reference

28 July 2017

83

1 reference

28 July 2017

30F-35F

1 reference

28 July 2017

9B

1 reference

Myocardial infarction in the familial forms of hypertriglyceridemia

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Triglycerides: a risk factor for coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Beyond LDL cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Small LDL, atherogenic dyslipidemia, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Structure and biochemical effects of fenofibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Efficacy and safety of ciprofibrate in hyperlipoproteinaemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Mechanism of the hypolipemic effect of clofibrate in postabsorptive man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Effects of combined bezafibrate-simvastatin appraised in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Hotline sessions of the 21st European Congress of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-densi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Vete

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2900270-2

10.1016/S0002-9149(99)00270-2

7 January 2021

Identifiers

DOI

1 reference

release_dyg4k2r5kvahlfeb6enjjgy6ra

28 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dyg4k2r5kvahlfeb6enjjgy6ra

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference